Qingdao Haier Biomedical Co., Ltd. Class A 688139
SSE · China · Producer Manufacturing
CNY 35.85+0.66 (+1.88%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Haier Biomedical (SHA: 688139) showcased a portfolio of automated and digital solutions spanning key pharmaceutical R&D, production and quality control workflows at the ISPE Singapore Conference & Exhibition 2026, one of Asia's key pharmaceutical engineering events, held from August 20-21 at Suntec Singapore. At the center of the showcase, the automated –80°C storage solution made its international exhibition debut, while the pilot freeze dryer was also featured, underscoring how Haier Biomedica
Haier Biomedical (SHA: 688139) participated at the ISBT Congress 2026 in Kuala Lumpur, presenting its blood product portfolio and integrated workflow solutions to the global transfusion market. This participation highlights the company's leadership in delivering intelligent blood safety and smart management solutions powered by IoT technology.
Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, is making simultaneous presence at Europe Biobank Week 2026 in Prague, one of the most important conferences for the international biobanking community, and Interphex Week Tokyo 2026, Japan's largest pharma and biotech gathering.
Haier Biomedical (SHA: 688139) has been named the No. 1 Chinese brand in global life science laboratory equipment sales and No. 1 in overseas sales in the same category, according to 2025 data published by Euromonitor International. The dual ranking places Haier Biomedical at the front of a competitive global field and caps a three-phase international expansion that has delivered a compound annual growth rate exceeding 20 percent.
Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has officially published its 2025 annual report, posting full‑year revenue of 2.33 billion yuan (USD 340.77 million) with overseas revenue growing 17.9% year-on-year to 840 million yuan (USD 122.85 million), accounting for 36% of total revenue – a record high. Despite a complex global trade environment, Haier Biomedical delivered double‑digit growth across all international business sectors.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.